ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound.
The last earnings update was 37 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ENDRA Life Sciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
ENDRA Life Sciences's
is considered below, and whether this is a fair price.
Price based on past earnings
ENDRA Life Sciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
ENDRA Life Sciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
ENDRA Life Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ENDRA Life Sciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
ENDRA Life Sciences
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
ENDRA Life Sciences's finances.
The net worth of a company is the difference between its assets and liabilities.
ENDRA Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ENDRA Life Sciences has no long term commitments.
This treemap shows a more detailed breakdown of
ENDRA Life Sciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
ENDRA Life Sciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Francois Michelon has been the Chairman and Chief Executive Officer of ENDRA Life Sciences Inc. since July 2015. Mr. Michelon joined ENDRA in 2015. He has 20 years of healthcare technology experience in general management, operations, strategy and marketing across the diagnostic imaging, surgical instrument and dental sectors. He has extensive industry and executive experience. From 2012 to 2014, Mr. Michelon served as Vice President of Global Marketing for Biomet Corporation’s 3i division, a provider of oral reconstruction technologies. He was responsible for the upstream and downstream development of 3i’s global portfolio. From 2004 to 2011, Mr. Michelon served as Group Director of Global Services and Visualization for Smith & Nephew’s Advanced Surgical Devices division, where he led P&L’s in the B2B service and capital equipment sectors. From 1997 to 2004, he worked at GE Healthcare in a variety of upstream and downstream marketing roles. He also earned his Six Sigma Black Belt certification. Mr. Michelon earned an MBA from Carnegie-Mellon University and a BA in Economics from The University of Chicago.
Francois's compensation has been consistent with company performance over the past year, both up more than 20%.
Francois's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
ENDRA Life Sciences
management team in years:
The tenure for the ENDRA Life Sciences management team is about average.
Chairman & CEO
CFO & Secretary
Chief Technology Officer
Human Resources Leader
Chief Commercial Officer
Board of Directors Tenure
Average tenure and age of the
ENDRA Life Sciences
board of directors in years:
The tenure for the ENDRA Life Sciences board of directors is about average.
Board of Directors
Chairman & CEO
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by ENDRA Life Sciences insiders in the past 3 months, but not in substantial volumes.
Imagine Owning ENDRA Life Sciences (NASDAQ:NDRA) And Wondering If The 32% Share Price Slide Is Justified
Check out our latest analysis for ENDRA Life Sciences With zero revenue generated over twelve months, we don't think that ENDRA Life Sciences has proved its business plan yet. … It seems likely some shareholders believe that ENDRA Life Sciences will significantly advance the business plan before too long. … A Different Perspective While ENDRA Life Sciences shareholders are down 32% for the year, the market itself is up 3.1%.
Can We See Significant Institutional Ownership On The ENDRA Life Sciences Inc. (NASDAQ:NDRA) Share Register?
A look at the shareholders of ENDRA Life Sciences Inc. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … ENDRA Life Sciences is not a large company by global standards.
Can We See Significant Insider Ownership On The ENDRA Life Sciences Inc (NASDAQ:NDRA) Share Register?
A look at the shareholders of ENDRA Life Sciences Inc (NASDAQ:NDRA) can tell us which group is most powerful. … ENDRA Life Sciences is not a large company by global standards. … View our latest analysis for ENDRA Life Sciences
Who Are ENDRA Life Sciences Inc's (NASDAQ:NDRA) Major Shareholders?
In this article, I'm going to take a look at ENDRA Life Sciences Inc’s (NASDAQ:NDRA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Check out our latest analysis for ENDRA Life Sciences
When Will ENDRA Life Sciences Inc (NASDAQ:NDRA) Come Back To Market?
Today I’ve examined ENDRA Life Sciences’s financial data from its most recent earnings update, to roughly assess when the company may need to raise new capital. … NasdaqCM:NDRA Income Statement Jun 1st 18 When will ENDRA Life Sciences need to raise more cash? … My cash burn analysis suggests that, if ENDRA Life Sciences continues to spend its cash reserves at this current high rate, it’ll have to raise capital within the next 6 months, which may be a surprise to some shareholders.
How Should Investors React To ENDRA Life Sciences Inc's (NASDAQ:NDRA) CEO Pay?
Performance can be measured based on factors such as earnings and total shareholder return (TSR). … Most recently, NDRA delivered negative earnings of -US$7.46M , which is a further decline from prior year's loss of -US$3.14M. … Usually I would use earnings and market cap to account for variations in performance, however, NDRA's negative earnings reduces the usefulness of my formula.
With A -93.74% Earnings Drop, Is ENDRA Life Sciences Inc's (NASDAQ:NDRA) A Concern?
Investors with a long-term horizong may find it valuable to assess ENDRA Life Sciences Inc's (NASDAQ:NDRA) earnings trend over time and against its industry benchmark as opposed to simply looking at a sincle earnings announcement at one point in time. … NasdaqCM:NDRA Income Statement Apr 16th 18 We can further assess ENDRA Life Sciences's loss by looking at what the industry has been experiencing over the past few years. … Each year, for the past five years ENDRA Life Sciences has seen an annual decline in revenue of -18.39%, on average.
What You Must Know About ENDRA Life Sciences Inc's (NASDAQ:NDRA) Major Investors
With hardly any institutional ownership, NDRA stock poses limited concern relating to the effect institutional block trades have on its stock price. … Private Company Ownership Another important group of owners for potential investors in NDRA are private companies that hold a stake of 1.46% in NDRA. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: Institutional ownership level and composition in NDRA is not high nor active enough to significantly impact its investment thesis.
When Will ENDRA Life Sciences Inc (NASDAQ:NDRA) Run Out Of Money?
See our latest analysis for ENDRA Life Sciences What is cash burn? … NasdaqCM:NDRA Income Statement Feb 27th 18 When will ENDRA Life Sciences need to raise more cash? … According to my analysis, if ENDRA Life Sciences continues to grow at this rate, it will burn through its cash reserves by the next 2.1 years, and may be coming to market again.
Does ENDRA Life Sciences Inc's (NASDAQ:NDRA) CEO Pay Reflect Performance?
Performance can be measured based on factors such as earnings and total shareholder return (TSR). … In the past year, NDRA delivered negative earnings of -$3.8M , which is a further decline from prior year's loss of -$2.5M. … Typically I'd use market cap and profit as factors determining performance, however, NDRA's negative earnings reduces the effectiveness of this method.
ENDRA Life Sciences Inc. develops medical imaging technology based on the thermos-acoustic effect that improves the sensitivity and specificity of clinical ultrasound. It offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person’s body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. It also offers Nexus-128 system that combines light-based thermos-acoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. ENDRA Life Sciences Inc. has collaborative research agreement with General Electric Company. The company was incorporated in 2007 and is based in Ann Arbor, Michigan.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.